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Abstract 
 
 
 
Background Darier Disease is a rare autosomal dominant disorder, which predominantly 
affects the skin of individuals regardless their gender or ethnicity. Clinical manifestations 
usually involve nail abnormalities and focal skin lesions such as greasy, brownish-redish 
keratotic papules, which are distributed in seborrheic areas of the body. Affected individuals 
are usually heterozygous for mutation in ATPase sarcoplasmic/endoplasmic reticulum 
Calcium transporting 2 (ATP2A2) gene, responsible for encoding Sarco/Endoplasmic 
Reticulum Calcium ATPase 2 (SERCA2). Although ATP2A2 mutations significantly reduce 
ER Ca2+ stores in both lesional and non lesional keratinocytes, scientists suggest that a 
threshold in ER Ca2+ depletion is required to disrupt adhesion molecules, as seen in lesional 
epidermis. Nonetheless, DD hallmarks (acantholysis and dyskeratosis) remain to be fully 
elucidated. Haploinsufficiency or dominant-negative effect are the postulated pathogenic 
mechanisms. 
Objective This study consists in the molecular characterization of a two-generation 
Portuguese family with DD history, including co-associated phenotypes and intrafamilial 
phenotypic variability.  
Methods All exons and intron-exon borders of ATP2A2 were bidirectionally sequenced 
from DNA and RNA extracted from the five subjects enrolled in this study (four affected 
individuals and one unaffected individual). Relative levels SERCA2 mRNA and protein were 
quantified by RT-qPCR and western blotting, respectively. 
Results  A splice-site mutation (c.1287+1G>T or IVS10+1G>T) was identified in all 
four affected individuals, who carry the mutation in heterozigosity, whereas the unaffected 
individual was shown to carry the wild-type ATP2A2 sequence in both alleles. This mutation 
leads to the skipping of full exon 10, which consequently generates a frameshift followed by a 
premature translation termination codon in exon 11. Results from RT-PCR of a fragment 
spanning exons 8-13 suggest that a small amount of the mutant transcript escapes NMD and 
less than 50% expression of the wild-type transcript is detected. In agreement, relative wild-
type and mutant SERCA2 mRNA expression levels assessed by qPCR revealed wild-type 
gene expression alone revealed a 36% expression, while mutant mRNA expression exhibited 
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residual levels of 18%. In contrast, western blot results showed 40 to 50% expression of wild-
type SERCA2 (115 kDa) in DD patients when compared to the healthy individual, while no 
sign of the putative mutant SERCA2 (45 kDa) was detected. These findings suggest that 
despite the escape of a small portion of abnormal SERCA2 mRNA from NMD, there is still no 
generation of mutant protein. Therefore, haploinsufficiency appears to be the mechanism 
underlying DD pathology in these patients. Finally, no genotype-phenotype correlations were 
found; however, this study contributed to alert physicians to the wide range of defects 
predicted by ATP2A2 mutations, including neuropsychiatric features, hearing loss, corneal 
viral infections by HSV, and glomerular nephritis which is, to the best of our knowledge, here 
firstly reported in association with DD. 
Conclusion As the first study of Portuguese patients, it adds knowledge to the worldwide 
mutational and clinical spectrum of DD and, importantly, contributes to genetic counseling 
since it allowed to discard a possible carrier status of the unaffected member of the family. 
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Resumo 
 
 
Introdução A doença de Darier é uma genodermatose rara, de transmissão autossómica 
dominante, que não distingue sexo ou etnia. As manifestações clínicas caraterísticas desta 
doença envolvem anomalias nas unhas e lesões cutâneas focais, tais como pápulas 
queratóticas acastanhadas-avermelhadas distribuídas pelas áreas seborreicas do corpo. Os 
indivíduos afetados são geralmente heterozigóticos para uma mutação no gene ATP2A2, 
responsável pela codificação da proteína SERCA2. Embora as mutações no gene ATP2A2 
reduzam significativamente as reservas de Ca2+ no retículo endoplasmático em células 
lesionadas e não lesionadas, os cientistas sugerem a necessidade de um limite na depleção 
destas reservas para interferir no funcionamento de moléculas de adesão, como observado nos 
queratinócitos acantolíticos da epiderme lesionada.  Haploinsuficiência ou efeito dominante 
negativo são os mecanismos patogénicos postulados para o fenótipo de Darier. 
Objetivo Este projeto consiste na caraterização molecular duas gerações de uma família 
Portuguesa de com histórico de doença de Darier, incluindo co-fenótipos e variabilidade 
fenotípica intrafamiliar. 
Métodos Todos os exões e limites exão-intrão do gene ATP2A2 foram sequenciados 
bidirecionalmente a partir de DNA e RNA extraídos dos cinco indivíduos envolvidos neste 
estudo (quatro afetados e um não afetado). Os níveis relativos de RNA mensageiro e proteína 
SERCA2 foram quantificados por PCR em tempo real e Western blotting, respetivamente. 
Resultados A mutação patogénica (c.1287 + 1G> T ou IVS10 + 1G> T) foi identificada 
em todos os quatro indivíduos afetados, que exibem a mutação em heterozigotia, enquanto o 
indivíduo não afetado exibe a sequência normal de ATP2A2 em ambos os alelos. A mutação 
altera o splicing e leva à eliminação completa do exão 10, que consequentemente altera a 
leitura da ORF, seguida de um codão de terminação de tradução prematura no exão 11. Os 
resultados de RT-PCR, correspondente à amplificação de um fragmento abrangendo os exões 
8 a 13, sugerem que uma pequena quantidade do transcrito mutado consegue escapar ao NMD 
e que a expressão de transcrito normal é inferior a 50% relativamente ao indivíduo normal. 
Em conformidade, os níveis relativos de expressão de RNA mensageiro SERCA2 normal e 
mutado avaliados por PCR em tempo real revelaram 36% de expressão do gene normal, e 
aproximadamente 18% de expressão do transcrito mutado. Em contraste, os resultados de 
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western blot mostraram 40 a 50% de expressão de SERCA2 normal (115 kDa) nos indivíduos 
com a doença, em comparação com o indivíduo saudável, enquanto nenhum sinal da 
hipotética proteína mutada (45 kDa) foi detetado. Em geral, os resultados obtidos sugerem 
que, apesar da pequena porção de transcrito mutado escapar ao NMD, não há tradução em 
proteína mutada, ou esta deve ser imediatamente degradada. Portanto, a haploinsuficiência 
parece ser o mecanismo responsável pela patologia de Darier nos doentes estudados. 
Finalmente, não foi possível identificar qualquer correlação genótipo-fenótipo; no entanto, 
este estudo contribuiu para alertar os médicos dermatologistas sobre a panóplia de alterações 
provocadas pelas mutações no gene ATP2A2, incluindo sintomas neuropsiquiátricos, perda de 
audição, infeções virais da córnea causadas por HSV, e nefrite glomerular membranosa que é, 
pelo que temos conhecimento, relatado neste trabalho pela primeira vez em associação com 
DD. 
Conclusão Como primeiro estudo em doentes Portugueses, esta investigação acrescenta 
conhecimento ao espetro mutacional e clínico mundial da doença de Darier e, mais 
importante, contribui para o aconselhamento genético, uma vez que permitiu descartar um 
possível estatuto de portador do membro não afetado da família. 
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 1 
 
1.  Introduction 
 
 
 This dissertation describes the first molecular characterization of a Portuguese family, 
in which a rare autosomal dominant disorder, known as Darier Disease (DD, OMIM 
#124200), segregates. Below, a number of topics will be discussed in order to present a clear 
background of the disease.  
 
1.1 Historical Aspects and Epidemiology  
 
 Darier Disease, also known as Darier-White disease or keratosis follicularis, 
predominantly affects the skin of individuals regardless their gender or ethnicity [1]. It was 
discovered in 1889 by Ferdinand-Jean Darier (1856-1938), a French physician, pathologist 
and dermatologist, and by the American dermatologist James Clarke White (1833-1916), 
independently [2, 3]. While White described a case of DD, Darier reported a similar case [3]. 
On one hand, White was the first to suggest the genetic nature of the disease once his patient’s 
daughter started to show similar skin lesions [3]. Darier, on the other hand, was the first to 
describe the dyskeratotic aspect of the lesional regions in the epidermis [2]. 
 The incidence of Darier disease has been scarcely investigated. According to the 
statistics, DD’s incidence can range from 1 in 30 000 to 1 in 100 000, worldwide. In the 
British population, the prevalence of the disease is 1 in 55 000, while it is estimated at 1 in 30 
000 in Scotland, and 1 in 100 000 in Denmark [4–6]. Despite the current studies about DD’s 
incidence in the North of Europe, an increasing number of mutational analyses and case-
reports involving patients from other geographic areas such as Japan, Tunisia, and Taiwan 
have been described [7–9]. 
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1.2  Epidermis and Calcium Signaling 
 
 Representing the largest organ in the human body, the skin provides a primary barrier 
not only against physical and chemical damage but also against pathogens [10]. The skin 
comprises three distinct layers: the innermost layer subcutis, the dermis, and the outermost 
layer epidermis [11].  Epidermis is where keratinocyte differentiation takes place in order to 
regenerate this skin layer. Keratinocytes are the predominant cells of epidermis, responsible 
for producing keratin and protecting the skin from chemical and mechanical damage. They 
proliferate by mitosis in the stratum basale, where they are held to each other and to 
desmosomes of the underlying dermis. After proliferation, keratinocytes differentiate by 
undergoing major biochemical and morphological changes until they reach the stratum 
corneum, where they finally die and leave the skin surface by shedding [10, 11].  
 Calcium (Ca2+) plays a major role in all cutaneous layers and is required for the 
regulation of keratinocyte’s proliferation. Throughout epidermis, the Ca2+ gradient increases 
substantially from the stratum basale to the stratum granulosum, where it reaches its peak, 
and then drops bluntly to zero in the stratum corneum, which is made of dead keratinocytes 
(Figure 1) [12]. In the presence of deregulated intracellular Ca2+ levels, the epidermal 
stratification is desynchronized and the texture of the skin becomes abnormal [10], which has 
been observed in skin disorders, such as Darier Disease, where endoplasmic reticulum (ER) 
Ca2+ stores happen to be depleted [13]. 
 The controlled Ca2+ release from the ER Ca2+ stores creates the luminal environment 
needed for crucial biological activities such as protein folding [14], cellular proliferation, 
apoptosis, and differentiation [15], and excitability and synaptic plasticity in neurons [16]. To 
function as a dynamic Ca2+ pool and allow immediate electrical or chemical signaling events 
in neurons, the ER must express three distinct types of proteins [14]. These proteins include 
Ca2+ pumps that actively promote Ca2+ transport from the cytosol to the lumen of the ER, 
known as Sarcoplasmic/Endoplasmic Reticulum Calcium ATPases (SERCAs), inositol-1,4,5-
triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) which control the release of 
ER Ca2+ to the cytosol along its electrochemical gradient.  
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Figure 1 | Intracellular and extracellular calcium concentration profile and differentiation markers along the 
epidermal strata (X100 Hematoxylin and Eosin staining) (https://basicmedicalkey.com/skin-6/#ch18lev9) [11, 
12]. 
 
  
 To prevent compromising the normal function of the ER, whenever stress is triggered 
by a disruption in Ca2+ homeostasis, an unfolded protein response (UPR) is initiated. If the 
stress is either consistent or too severe, the UPR will not be strong enough to overcome it 
[14]. Consequently, apoptosis is induced to eliminate the damaged cell, which usually occurs 
in DD and neurodegenerative diseases [14]. 
 In normal conditions, there are molecular mechanisms that help preventing ER Ca2+ 
depletion or overload. Ca2+ release from the ER in response to physiological stimuli evokes 
mitochondrial activity, leading to the increase of ATP synthesis, and to an initial deficit of 
Ca2+ concentration in the ER. Stromal-interacting molecule (STIM), a protein localized in the 
ER membrane, senses this deficit and interacts with the plasma-membrane and Ca2+ channel 
ORAI1 (calcium released-activated calcium channel protein 1), enabling store-operated Ca2+ 
entry (SOCE) [13, 14, 17]. Hence, while Ca2+ is being released from the ER, there will be 
more Ca2+ entering the cell. Once SOCE increases cytosolic Ca2+ levels, SERCA proteins use 
ATP to actively pump calcium into the ER, in order to reduce cytosolic Ca2+ levels and 
restore ER Ca2+ levels, allowing ER-related processes to continue properly [14].  
 Under pathological conditions, impairment in SERCA activity is sufficient to 
compromise steady-state Ca2+ levels in the ER, along with its functions, leading to ER Ca2+ 
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depletion. The importance of ER calcium stores controlled by Sarcoplasmic/Endoplasmic 
Reticulum Calcium ATPase 2 (SERCA2) was first revealed by a lethal phenotype of 
SERCA2 knockout mice, whose ER calcium levels were increasingly depleted [18]. In vitro 
experiments, where normal epidermal cell lines under inhibition of SERCA2 were cultured 
with low calcium media and then switched to high calcium media, have also shown the 
importance of SERCA2-gated Ca2+ stores [19]. Nevertheless, it appears that the human body 
has its ways to compensate for SERCA2 loss, as can be observed in most DD patients. 
 
 
 1.3   Gene and Protein 
 
 The inherited character of Darier disease relies on a heterozygous mutation in the 
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 (ATP2A2) gene, which 
encodes the SERCA2 protein. ATP2A2 mutations lead to the depletion of ER Ca2+ stores, 
particularly in keratinocytes since these are frequently exposed to ER stressors such as UVB 
light [1, 13]. Located in chromosome 12q23-24, ATP2A2 is transcribed into 21 exons and 
alternative splicing of the resulting pre-mRNA generates three major isoforms: SERCA2a, 
SERCA2b, and SERCA2c [1, 20]. Alternative splicing of exon 20 leads to the production of 
SERCA2a and SERCA2b isoforms, while the inclusion of a short intronic sequence 
containing an in-frame STOP codon between exons 20 and 21 of SERCA2a originates 
SERCA2c [13, 20].  
 SERCA2, along with SERCA1 and SERCA3, belong to P-type superfamily of Ca2+ 
pumps that can be detected in the majority of eukaryotic cells’ sarcoplasmic/endoplasmic 
reticulum. These pumps share a highly conserved general structure, which consists of three 
cytosolic domains – actuator domain (A), nucleotide-binding domain (N), and 
phosphorylation domain (P) – and a transmembrane domain (TM), where Ca2+ binding sites 
are located (Figure 2) [15]. These pumps also share the same reaction cycle which starts with 
the binding of two calcium ions to the Ca2+ binding sites that are facing the cytoplasm, 
followed by the binding of one ATP molecule to the N domain and posterior hydrolysis by P 
domain, leading to the phosphorylation of a highly conserved aspartic acid residue (Asp351) 
(Figure 3) [15, 21]. This auto-phosphorylation allows the pump to switch conformation so its 
Ca2+ binding sites can face the luminal space and release the calcium ions into the ER. The 
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pump is regenerated to its initial state through dephosphorylation of the P domain, catalyzed 
by H2O and the conserved glutamate in the A domain [15, 21].  
 
 
 
 
 
Figure 2 | Overall topology of the P-type ATPase calcium pump SERCA. (A) The cytoplasmic headpiece 
comprises the nucleotide binding (N), phosphorylation (P) and actuator (A) domains. The ATP binds to the N 
domain. The conserved aspartic acid that gets phosphorylated is in the P domain. The calcium binding sites are 
located in the transmembrane (TM) domain. The TM domain is made of ten TM helices (labeled M1 to M10 or 
11). (B) The A domain is covalently linked to the helices M1, M2 and M3, and the P domain is covalently linked 
to the helices M4 and M5. Adapted from [22]. 
 
 
 Furthermore, several studies have demonstrated, through radiation inactivation 
analysis and optical diffractometry, that these ATPases appear to be organized as dimers in 
the sarcoplasmic/endoplasmic membrane [23–26]. Nevertheless, it has not been proved 
whether monomers are not sufficient for normal function of the pump.  
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Figure 3 | Reaction cycle for the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) pumps. During this 
cycle, a series of biochemical reactions lead to two major conformational states of the Ca2+ pump: an E1 state 
when two high-affinity Ca2+ -binding sites that are facing the cytoplasm become saturated, and an E2 state where 
the Ca2+ -binding sites have a low-affinity and therefore switch to the opposite side and Ca2+ is released to the 
lumen. During each cycle, two Ca2+ ions are pumped for each ATP hydrolyzed. (Adapted from 
http://www.cellsignallingbiology.org/csb/005/csb005fig5_SERCA_pump_cycle.htm?resolution=HIGH). 
 
  
 Despite their similarities, these pumps do not share a common expression pattern, and 
neither do SERCA2 splice variants. SERCA2a (997 amino acids) has been found to be 
restrained to cardiomyocytes, cardiac slow-twitch muscle, skeletal and smooth muscle, 
pancreatic, and cerebellar Purkinje neurons (http://www.uniprot.org/uniprot/P16615) [13]. It 
is expressed at lower levels in the epidermis and has a two-fold lower affinity for Ca2+ and a 
two-fold higher catalytic turnover rate, when compared to SERCA2b [27]. The reduced 
expression of isoform SERCA2a, found in animal models of heart failure and in humans with 
heart failure, confirms its essential role in platelet and cardiac function [28]. In fact, in healthy 
individuals, SERCA2a is usually expressed at elevated levels in the heart and represents a key 
player in cardiac myocyte Ca2+ regulation required for excitation contraction coupling [28]. 
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 Mutations in the ATP2A2 gene affecting SERCA2a levels should therefore provoke an 
augment in platelet aggregation and cardiac dysfunction. However, there is a clear paradox 
since DD patients have been shown to have a normal cardiac function and platelet activity 
[28]. Researchers suggest that SERCA3, which is also present in platelets, may compensate 
for the platelet SERCA2a deficit in DD patients [29]. 
 SERCA2b (1042 amino acids) is the ubiquitous housekeeping isoform, expressed in 
non-muscle cells and highly expressed in epidermal cells [1, 29]. Comparing to SERCA2a, 
isoform b contains an additional transmembrane domain, encoded by exon 21, and a tail 
known as 2b tail, which extends to the lumen of the ER. Interestingly, SERCA2b has the 
highest affinity for Ca2+ among all splice variants [27]. Moreover, a mutation in exon 21, 
affecting only SERCA2b isoform’s expression appears to be enough to cause DD, suggesting 
the crucial role of this pump in the skin and the inability of other splice variants to 
compensate the loss of SERCA2b normal function [13]. Nevertheless, it has been proposed 
the existence of putative compensatory mechanisms in DD keratinocytes, such as secretory 
pathway Ca2+-ATPase pump type 1 (SPCA1), that may help overcoming the intracellular 
[Ca2+] imbalance caused by mutations in the ATP2A2 gene [30]. 
 The latest isoform described, SERCA2c (999 amino acids), is expressed in epithelial, 
mesenchymal and hematopoietic cell lines and monocytes [24, 28]. This isoform shows a 
Ca2+ affinity and catalytic turnover rate similar to that of SERCA2a and SERCA2b, 
respectively [20]. 
 According to Leiden Open Variation Database v3.0 (http://www.lovd.nl/3.0/home), 
420 variants have been reported in the ATP2A2 gene. DD mutations are mostly private ones 
(Figure 4). The majority of these private variants are missense mutations, which have been 
reported to be associated with a more severe phenotype [13, 31]. Mutations yielding a 
premature stop codon, nonsense, and splice-site mutations, and in-frame deletions and 
insertions have also been reported in DD patients [13]. Depending on the protein domain 
affected by these mutations, one may suggest a series of functional disruptions, including loss 
of Ca2+ affinity, obstruction of Ca2+-binding sites, decreased ATP affinity, effects in 
phosphorylation by ATP and Pi, effects on conformational shifts, inhibition of 
dephosphorylation, or disassembling of Ca2+ transport from ATP hydrolysis [32].  
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Figure 4 | Schematic representation of ATP2A2 gene and encoded protein SERCA2 isoform b and 
spectrum of ATP2A2 variants responsible for DD. All 21 exons and respective protein domains are 
represented. S- Stalk domain, M – Transmembrane domain. Exons 5, 10, 15, and 20 are numbered in the 
ATP2A2 gene representation. The spectrum of ATP2A2 variants below the gene and protein schemes refer to 
exon 20 as “20a” and exon 21 as “20b” [33]. 
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1.4  Clinical Manifestations 
 
 DD runs a chronic and relapsing course after its onset and may aggravate with age [5, 
13]. The onset of the phenotypic abnormalities is usually during the first or second decade of 
life; however, delayed onset may happen as it has been reported [4, 6]. The disease is 
characterized by nail abnormalities and focal skin lesions such as greasy, skin-colored (brown 
or yellow) keratotic papules and eruptions (Figure 5) [1, 34]. The majority of skin lesions are 
distributed in seborrheic areas of the upper back, folds, neck, scalp, chest, and face. These 
lesions become easily infected, leading to major discomfort and exacerbation of the condition. 
Once infected, there is a high prevalence of Staphylococcus aureus colonization in these 
lesions [35]. Furthermore, external factors such as UVB radiation, heat, friction, sweat, and 
humidity play a key role in the worsening and relapse of skin lesions [1, 13, 34]. The nail 
phenotype consists of longitudinal splitting with V-shaped notches at the free margin of the 
nail, and subungual hyperkeratosis [1]. Palmoplantar pits are quite common, and 
hyperkeratosis of palms and soles may also occur. Moreover, the oral mucosa and gingiva 
may also suffer from lesions [1]. However, the above-mentioned clinical manifestations vary 
in severity from patient to patient and even within affected members of the same family. 
 
 
1.5  Histopathology 
 
 Although genetic testing is the most accurate method to diagnose a genetic disorder, 
the diagnosis of DD is usually done by histological examination of a skin biopsy [36]. 
Histologically, two hallmarks of DD can be identified in focal epidermal lesions: (1) 
acantholysis, which consists of loss of cell-to-cell adhesion and suprabasal clefting as a result 
of desmosomal disintegration; (2) dyskeratosis, characterized by abnormal/premature 
keratinocyte differentiation and apoptotic keratinocytes called “corps ronds” with a central 
basophilic and pyknotic nucleus surrounded by a clear halo (Figure 6) [1, 42]. Acantholysis 
can be observed in more detail by electron microscopy analysis, which demonstrates an 
impaired number of desmosomes and desmosomal cadherins [5, 43]. Desmosomes are 
intercellular junctions, composed by adhesion molecules such as cadherins and desmosomal 
plaque proteins, responsible for connecting adjacent cells. These cellular structures are 
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essential in mammals’ cardiac and epithelial tissues since these are subject to mechanical 
stress [39]. Therefore, disruption in the stability and cell surface expression of desmosomal 
proteins contributes to acantholysis since it impairs cell-to-cell adhesion in lesional 
keratinocytes. Additionally, cadherins are known for their important role in neuronal 
functions including the formation of specific neural circuits [40].  
 
 
 
 
 
Figure 5 | Clinical manifestations of Darier disease patients. A Reddish, greasy, crusted papules on the 
abdomen. Adapted from [41]. B Confluent reddish-brownish papules in the seborrheic areas of the chest, 
submammary areas, and arms. Adapted from [42].  C Papular lesions cover skin in the occipital area of female 
patient with Darier’s disease. Adapted from [43]. D Nail involvement in Darier’s disease. Adapted from [1]. E 
Involvement of lower limbs with marked keratosis and fissures, which may lead to secondary infection in a 
patient with extremely severe condition. Adapted from [44]. F Papillomatous and macerated lesion in the groin. 
Adapted from [45]. 
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 Studies, where authors used thapsigargin as a specific inhibitor of SERCA or small 
interfering RNA directed to SERCA2, have provided evidence for the intrinsic role of 
SERCA2 in the disruption of intracellular Ca2+ signaling and consequent mislocalization of 
desmosomal cadherins [19, 34, 46, 47]. Nevertheless, the intracellular Ca2+ role in the 
regulation of adhesion molecules needs further investigation, as well as the role of cadherins 
in acantholysis and dyskeratosis in lesional keratinocytes.  
 
 
 
 
 
 
 
Figure 6 | Histological section of Darier disease skin. Skin biopsy from Darier disease where a suprabasal cleft 
of the epidermis formed by acantholytic cells can be observed, as well rounded dyskeratotic cells with a dark 
nucleus, so called “corps ronds”, and hyperkeratosis. B is an enlargement of A. Adapted from [13]. 
 
 
1.6  Associated Manifestations 
 
 Although skin lesions represent the major pathophysiological outcome of mutations in 
the ATP2A2 gene, additional clinical manifestations appear to be linked to DD, being 
neuropsychiatric features the most common co-occurrences.  
 
 
 
 
B 
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 1.6.1  Neuropsychiatric manifestations 
 
 Interestingly, the impairment of Ca2+ homeostasis and connectivity defects due to 
cadherin disruption are involved in cognitive and psychiatric disorders [45, 48, 49]. In fact, a 
range of neuropsychiatric features such as depression, suicidal behavior, bipolar disorder, 
schizophrenia, intellectual disability, epilepsy, cognitive deficit, mental retardation, and 
learning disability have been reported in DD patients [48–51]. A study involving unrelated 
DD patients revealed that 31% of these have a lifetime history of suicidal thoughts and 13% 
have attempted suicide, which did not have a relationship with DD or worsening of the 
disease [52]. Gordon-Smith et al. have found higher lifetime prevalence rates of mood 
disorders (50%), especially major depression (30%) and epilepsy (3%), to be present within a 
sample of one hundred unrelated DD patients compared with that in the general population 
[52]. In agreement with these findings, Celik et al. highlighted that the overall prevalence of 
epilepsy is 30–42.9 in 1000 DD patients, while the reported lifetime prevalence rates of 
epilepsy in the general population are variable, with a percentage of 1.3% [53]. 
 Mutational analysis of a number of DD patients with neuropsychiatric phenotypes has 
shown predominance of missense mutations affecting the ATP-binding domain, between 
exons 13 and 19 of the ATP2A2 gene, whereas patients with DD alone have demonstrated a 
more diverse series of mutations predominantly spread between exon/intron 1 and 19 [32]. 
Therefore, it is suggestible that missense mutations in the ATP-binding domain turn out to be 
crucial contributors for abnormalities in neuron signaling. Nevertheless, the reason why 
psychiatric phenotypes are not co-segregated among every family member with the same DD 
mutation remains to be unraveled. 
 Summing up, there are four reasons why these co-occurrences might be present in DD 
patients: (1) a predisposition of ATP2A2 gene mutation towards the neuropsychiatric illness; 
(2) ATP2A2 gene location near a susceptibility gene for the neuropsychiatric illness; (3) 
pleiotropic effects of SERCA2 since it is expressed in both epidermal and neuronal cells; or 
(4) by pure chance, given that the mentioned psychoses show a high prevalence worldwide 
[50].  
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 1.6.2  Other manifestations 
 
 Besides neuropsychiatric phenotypes, there are other potential associated 
manifestations in DD that should keep dermatologists alert, such as renal impairment, 
testicular agenesis, cataracts, skin cancers, bone cysts, and corneal and ocular sequels [54–
57]. Some researchers even point out for the genetic nature of DD as a model of skin 
carcinogenesis since the disruption of Ca2+ homeostasis, among other disturbances, is capable 
of inducing several genetic alterations, as it has been observed in cutaneous tumorigenesis 
models [58]. Opposite to the major mechanism of cancer, in ATP2A2+/- mice, neither RAS nor 
P53 proto-oncogenes were mutated, suggesting a novel form of cancer susceptibility through 
mutated SERCA2 [59]. This evidence is in agreement with a case report about a DD patient 
who had no history of smoking, drugs, or familial history of cancers, and still developed a 
squamous cell carcinoma (SCC) in the same area of a skin lesion, suggesting that SCC and 
DD may share common molecular disruption mechanisms [58].  
  Increasing literature gives more and more evidence that these secondary 
manifestations are unlikely to occur by mere chance in DD patients. However, further 
research is needed to clarify the mechanisms underneath these co-phenotypes and their 
genetic predisposition. 
 
 
1.7  Intrafamilial phenotypic variability 
 
 The incidence and severity of skin lesions are not equally observed from parent to 
child, or sibling to sibling, who carry the very same pathogenic mutation in the ATP2A2 gene. 
Furthermore, despite the linkage between neuropsychiatric phenotypes and DD, the formers 
are not co-segregated in every affected member of the family. Researchers highlight for the 
presence of nucleotide alterations in the ATP2A2 gene, apart from the pathogenic mutation, as 
a potential cause for such clinical variability between relatives [30]. Although phenotypic 
variability can be observed in several families that segregate the disease, linkage studies 
embracing this matter are scarce and well-defined genotype-phenotype correlations have not 
yet been achieved.  
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1.8  Mechanism of Action 
  
 Throughout literature, haploinsufficiency or dominant-negative effect have been the 
postulated pathogenic mechanisms of DD, which is characterized by a heterozygous mutation 
in the ATP2A2 gene in most patients. According to haploinsufficiency, a single wild-type allele 
is not able to provide enough amount of protein and thus does not allow normal cell viability 
or function. However, if haploinsufficiency ought to be enough to cause DD, then why is the 
onset during the first or second decade of life rather than at birth? Why does DD lead to focal 
lesions rather than generalized dermatoses? How can SERCA2 haploinsufficiency explain the 
variable clinical severity among family members who carry the same mutation? All these 
observations have led scientists to further investigate the effect of DD mutations and/or 
SERCA2 inhibition.  
 Increasing in vitro studies involving epidermal and other cell types treated with 
SERCA-specific inhibitors, siRNA directed to SERCA2 mRNA, or site-directed mutations in 
ATP2A2 gene have demonstrated that SERCA2 haploinsufficiency may not be enough to 
cause DD [19, 60, 61]. SERCA2 mutants studied in neuronal and epidermal cell lines 
revealed to be insoluble or partially soluble due to their misfolded state, intrinsic to the 
mutation itself [60]. Instead of being degraded by proteasomes, the insoluble SERCA2 
mutants have shown to gather around the nucleus, originating aggregates that contribute to the 
rounding up of cells seen in DD epidermis [60]. On the other hand, the perinuclear 
aggregation of these proteins could rely on the ability of SERCA2 mutant monomers to 
interact with the wild-type encoded SERCA2 in order to form dimers, as it has been 
demonstrated by co-immunoprecipitation of SERCA2 mutants and wild-type proteins from 
human embryonic kidney cells co-transfected with both SERCA2b plasmids [61]. Ahn et al. 
suggest that different ATP2A2 mutations may lead to different SERCA2 mutants, which may 
be responsible for the different phenotypes in DD patients according to the mutation’s impact 
on the activity of the wild-type encoded pump. This study reveals that most mutants not only 
interact with wild-type SERCA2 to form a dysfunctional dimer but also inhibit the rate of 
Ca2+ uptake by wild-type SERCA2, causing a dominant-negative effect [61].  
 Interestingly, it has been demonstrated that both lesional and non-lesional DD 
keratinocytes suffer ER Ca2+ depletion, but only lesional keratinocytes exhibit mislocalization 
and altered trafficking of desmosomal cadherins (DCs) [19, 34]. This aspect of DD’s 
pathology was enlightened by Li et al. who revealed that inhibition of SERCA2 by 
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thapsigargin in human epidermal keratinocytes leads to the reduction of ER Ca2+ levels below 
a threshold level, which consequently causes ER retention of nascent DCs [19]. Furthermore, 
it has been shown that the maturation (ER-to-Golgi transport) of nascent DCs is not affected 
when SERCA2 activity was inhibited by siRNA, suggesting that haploinsufficiency does not 
cause enough ER Ca2+ depletion to disrupt adhesion in DD pathology [19]. Presenting similar 
results, Celli et al. have reported that treatment of normal cells cultured with thapsigargin can 
disrupt the assembly of desmoplakin and E-cadherin to cell-to-cell boarders in a dose-
dependent manner [34]. However, since thapsigargin not only blocks SERCA2 but all other 
SERCA pumps’ activity, it would be worth to further investigate the assembly of cadherin 
molecules in SERCA2 mutant cells.  
 Another hallmark of DD is the abnormal differentiation that occurs in lesional 
keratinocytes, including hyperproliferation and apoptosis of these cells. It is not surprising 
that once Ca2+ profile along the epidermis is disrupted, Ca2+ dependent activities such as 
differentiation, proliferation and apoptosis become deregulated. Calcium signaling may as 
well be crucial not only to the differentiation markers in each epidermal stratum, but for the 
BCL2 family which is linked to apoptosis. Bongiorno et. al have found decreased levels of 
BCL2 and BCL-xL, and deregulated levels of BAX in histological specimens of DD [62]. 
These results may explain the presence of “corps ronds” in histological sections in lesional 
epidermis. In addition, BCL-2 was shown to upregulate and possibly interact with SERCA 
pumps in order to preserve and stabilize ER Ca2+ pools, which is one of the ways that BCL-2 
protects cells from apoptosis [62]. These findings suggest that (1) once there is not enough 
SERCA2 localized in the membrane of the ER, BCL-2 is unable to interact with SERCA2 in 
order to maintain ER Ca2+ stores, which consequently subjects keratinocytes to apoptosis; (2) 
with the presence of deregulated BAX, BCL-2 is also deregulated; (3) a decreased level in 
BCL-xL may also contribute to apoptosis in keratinocytes and to abnormal mitotic process; 
and finally (4) the imbalance of these three apoptosis-regulator proteins may underline the 
apoptotic pathway responsible for dyskeratosis seen in DD [62]. Nonetheless, DD hallmarks 
remain to be fully elucidated.  
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1.9  Treatment 
 
 Heretofore there has not been found a treatment whose efficacy does not vary among 
DD population. Personal hygiene, the use of sunscreen and avoidance from solar exposure, 
heat, high humidity, and tasks that could lead to excessive sweat are some of the 
indispensable measures in the day life management of the disease [44]. Currently, oral or 
systemic retinoids are the most frequently prescribed drugs to manage DD. In some cases, 
these drugs are able to reduce hyperkeratosis and flatten the papular component of the skin 
eruptions effectively. However, in most cases, retinoids are associated with a large number of 
noxious side effects, including mucosal dryness, itching, and severe or worsening of 
psychiatric symptoms [39, 63, 64]. In addition, most retinoids cannot be prescribed to women 
of child-bearing age [41, 65].  
 To date, the conventional treatments (retinoids, emollients and corticosteroids) used to 
manage DD’s cutaneous manifestations have yield disappointing results in general. Efficacy, 
safety, and long-term absence of relapses are crucial factors for a successful treatment. 
Therefore, other alternative drugs and therapies have recently been tested in DD patients. 
 A promising retinoid is the vitamin A derivate drug, alitretinoin (9-cis retinoic acid), 
which has shown cutaneous improvement due to its anti-proliferative and immune-
modulatory effects on keratinocytes, and absence of relapse or relevant side effects within 15 
months [66]. As opposed to other retinoids, alitretinoin’s short half-life suggests that it could 
be used to treat females of childbearing age as well [66]. Abe et al. reported a great clinical 
response and safety of vitamin D3 analog, Tacalcitol, in a DD patient [63].  
 Furthermore, therapies used in cancer patients, such as photodynamic therapy and 5-
fluorouracil (5-FU), are also being tested in DD patients with benign or malignant skin 
lesions. Promising reports on treatment with topical 5-FU reveal that this compound is well 
tolerated by the majority of patients, who revealed a continuous decrease in cutaneous 
inflammation, and relief of burning and itching sensations caused by the condition of the 
disease [67]. 
 In a limited number of patients, photodynamic therapy (PDT) has been reported to be 
tissue selective and responsible for successful treatment of DD [65, 68]. PDT consists on the 
combination of a photosensitizer, usually topical 5-aminolaevulinic acid (5-ALA), which 
accumulates in the target cells, an activating light source, and oxygen which cause a photo-
oxidative reaction within the lesional tissue [65]. As a result, reactive oxygen species are 
 17 
generated, inducing apoptosis and necrosis of target cells. Unlike dermabrasion and laser 
therapies, PDT prevents the risk of scarring and relapse of the condition due to tissue 
selectiveness [65].  
 The compounds and therapies above-mentioned are excellent candidates to manage 
DD. The increasing promising reports involving single patient or small number sample trials 
have opened doors to possible wider trials in the future. Randomized clinical trials would be 
the best way to confirm the effectiveness and safety of these recently tested drugs [67]. 
 Additionally, there have been reported promising targets for DD, including 
sphingosine phosphate lyase (SGPL1), Transient Receptor Potential Canonical 1 (TRPC1), 
and cyclooxygenase-2 (COX-2), whose modulation could be a potential treatment for 
managing abnormal differentiation and loss of intercellular adhesion, keratinocyte 
proliferation, or for the enhancement of SERCA2 expression, respectively [34, 69, 70]. 
 Despite the progress in gene therapies for heritable skin disorders, there is a 
considerable need to target DD by correcting the underlying mutation in somatic cells, either 
by using interfering RNAs, adeno-associated virus, or even CRISPR [71, 72].  
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2.  Aims of the study 
 
 
 This project consists in the molecular characterization of a two-generation Portuguese 
family with DD history, including co-associated phenotypes and intrafamilial phenotypic 
variability. Accordingly, there are four aims that must be considered: 
 
 Aim no. 1: Identify and describe the pathogenic mutation that is causing the 
pathology in the family. 
 Aim no. 2: Examine whether the unaffected individual is a carrier but due to possible 
incomplete penetrance or later onset of the disease does not yet show clinical manifestations. 
 Aim no. 3: Analyze the pathogenic mutation’s effect at the transcriptional and 
translational levels. 
 Aim no. 4: Investigate genotype-phenotype correlations in an attempt to explain 
clinical heterogeneity of the affected family members by coupling the results from mutational 
analysis to their clinical history. 
 
 The results from this mutation analysis will determine whether the patients and 
possible carrier of the mutation should benefit from genetic counseling. Questions such as “Is 
this disease going to affect my children one day?”, “What should be monitored in my future 
children?” can eventually be brought up to surface and genetic counseling will help by inform 
them tightly about the risk of their progeny developing DD and co-occurrences, when 
planning or expecting to have a baby. 
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3.  Participants and Methods 
 
 
3.1  Case Report 
 
 Five individuals from the two-generation family agreed to enroll in this study: four 
affected relatives (I.2, I.3, II.1 and II.3) and one unaffected relative II.2 (Figure 7). Relatives 
I.1 and I.4 were not considered to integrate the following study since they do not show any 
clinical history of the disease.  
 
 
  
 
Figure 7 | Pedigree of the two-generation family. The affected individuals are denoted by solid black symbols 
whereas unaffected individuals are denoted by open symbols. Arrows point to the individuals who participate in 
this study.  
 
  
 All affected family members were diagnosed by dermopathology during their first 
decade of life. These individuals share a monomorphic dermatosis, notably symmetrical, 
containing multiple non-follicular hyperkeratotic papules with 2-4 mm in diameter, brownish, 
rounded and occasionally crusted, on skin usually healthy or erythematous skin during 
periods of inflammatory exacerbation. The lesions are distributed along the entire lateral 
cervical region, anterior thorax and lower abdominal region (especially flanks), appearing 
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also in the scalp, and predominant in retroauricular region. Palms of the hands present 
multiple millimetric depressions filled by keratin (palmar pits). Nails of the hands and feet 
present discrete longitudinal leukonychia, fragility, fissure and dyskeratosis with V-shaped 
notches on the distal end of the nail plate. Eventual relapses of greater clinical severity usually 
lead to skin eruptions or infections by bacterial agents. Patients clinical course is in agreement 
with the worsening of the disease over the years. Moreover, patients agree that skin lesions 
are exacerbated by sweat, friction, and sunlight, particularly during the summer.  
 However, the clinical severity of the disease varies from patient to patient. At the skin 
level, patient I.1 has more relapses than his brother (I.3) while patient II.1’s relapses are more 
frequently and more severe than those of his father (I.1). In addition to their skin phenotype, 
viral, immunologic, and neuropsychiatric features occur in most patients (Table 1).  
 To manage DD, the patients take medicines prescribed by dermatologists such 
emollients, topical antibiotics, and retinoids such as acitretin, a derivative of vitamin A. They 
also avoid being exposed to the sun during the summer in order to prevent focal lesions to 
emerge. Patients with other occurrences, referred in Table 1, take additional medicines to 
manage these. 
 
Table 1 | Additional information about participants’ actual age, age of onset, and other phenotypic 
manifestations. 
Individuals 
Actual 
Age 
Age of DD onset 
Neuropsychiatric 
occurrences 
Other occurrences / age of onset 
I.2 61 
1st decade of 
life, around six 
years old 
None 
Herpes simplex virus 
in the left eye / 39 
I.3 56 None None 
II.1 31 
Single suicide attempt 
Depressive moods 
Membranous glomerulonephritis / 21 
Left ear deafness 
II.3 34 Epilepsy Leukemia 
II.2 24 NA NA NA 
NA – not applicable 
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3.2  Sample collection 
 
 Peripheral blood was collected by venipuncture from the enrolled individuals and 
written informed consent was obtained from each one. In the case of the affected individuals 
that are followed by a dermatologist, respective doctors were informed about the study. Blood 
samples were used for the extraction of nucleic acids and preparation of protein homogenates. 
 
 
3.3  DNA and RNA extraction 
 
 Lymphocytes from a total peripheral blood volume of 14 mL from each subject were 
freshly isolated in a Ficoll density gradient and each pellet was stored at -80ºC before further 
use. Genomic DNA and total RNA were extracted from peripheral blood lymphocytes using 
Citogene ® DNA Blood Kit (Citomed) and Isol-RNA Lysis Reagent (5PRIME), respectively. 
The extraction of genomic DNA was performed based on a standard protocol involving 
cellular lysis, followed by protein precipitation, and DNA hydration. Total RNA extraction 
was performed according to the TRIzol method using chloroform to separate RNA from DNA 
and contaminants, followed by isopropanol precipitation, and pellet solubilization in RNase-
free water. DNA and RNA concentrations and A260:A280 ratio from each sample were assessed 
using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Quality and 
integrity of nucleic acids were also examined by 1% agarose gel electrophoresis. Extracted 
DNA samples were preserved at 4ºC before further use, while total RNA samples were stored 
at -80°C. 
 
 
3.4  PCR and RT-PCR amplification 
 
 Polymerase chain reaction (PCR) amplification of all 21 exons and flanking intronic 
boundaries of the ATP2A2 gene was performed using 17 sets of primers, specifically designed 
with Primer3 program (http://primer3.ut.ee) (Table 2).  
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Table 2 | PCR primers and related parameters for amplification of ATP2A2 from genomic DNA. 
a 
According to NCBI reference sequence NG_007097.2 
 
 
PCR conditions consisted in an initial denaturation at 98ºC for 30 s, followed by 35 
cycles of 98ºC for 10 s, an annealing temperature at either 55ºC or 58ºC for 10 s, and 
extension at 72ºC for 20 s; a final extension step for 5 minutes was performed. Each PCR 
reaction was carried out in a total volume of 25 μL containing nuclease-free water, PCR 
Exon Forward Primer Reverse Primer 
Coordinatesa          
(Forward; Reverse) 
Product 
size (bp) 
Annealing 
Temperature 
(ºC) 
1 gcaagaggaggaggggaga ccatcttccctggctctccc 5035-5053; 5322-5341 307 
58 
2+3 cctccctcttgacacattgct agacacagcttgcaactcca 5934-5954; 6268-6287 354 
4 catgttgggcaggttggtct ccattgcactccagcctg 15221-15240; 15683-15700 480 
5 tgtccttgtgtctgttgcct tgacaggaagggaggtgcta 19810-19829; 20280-20299 490 
6 ctcatttcagccgccttt aagggacagtgaggcaagag 46332-46349; 46514-46533 202 
7 ggtgggcatgaatgagaggt agtgatggttggcagtgaaa 49686-49705; 49915-49934 249 
8 cagcgtcggtatttaagttggg acaaagaaccacgacacgga 50862-50883; 51421-51440 573 
9 tgtttgcctttgtcctaagct tgccacaccagatcctttaaa 55876-55896; 56080-56100 225 
10 ggggcgggaggaatcaatag ctttcattccacccacccca 56492-56511; 56706-56725 234 
11 gacagattgtgcttttgtgga gagagtaggacagtgcagaca 57291-57311; 57579-57599 309 
12+13 ttgccacccagtagtatcca tgcagggtgtggacaaagaa 62617-61636; 63113-63132 516 
14 ggcaacaagagcgaaact gaggctactatgtgcttgtg 63941-63958; 64406-64425 478 
15 tttgccaagagacctacgg tttctgtcttgcccactccc 65482-65500; 65951-65970 483 
55 16 ttttctggaggagggcg agggcatctctgtcttttgc 66514-66530; 66920-66939 426 
17+18 ccggttaccatcactgtccc tgactacacacaattccccgg 68139-8158; 68808-68828 690 
19+20 tactgccactgtgacacgtg gaaatcccatcggtgcatgc 69311-69330; 69740-69759 449 
58 
21 tctagatgctaccctgtgtgg tcagtcatgcacagggttgg 73475-73495; 73754-73773 299 
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buffer (5x), 3.0 mM MgCl2, 3% dimethyl sulfoxide, 200 μM of deoxynucleotide triphosphate, 
0.5 μM of each primer, 1.0 unit of Phusion® High-Fidelity DNA Polymerase (New England 
Biolabs), and approximately 200 ng of genomic DNA. To assure PCR products were 
amplified with the right dimension, an aliquot of each sample was run on a 2% agarose gel. 
Total RNA isolated from lymphocytes was reverse transcribed using the Maxima First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Each RT-PCR reaction was prepared 
using a Reaction Mix containing reaction buffer, deoxynucleotide triphosphates, single-
stranded 18-mer oligonucleotides and random hexamer primers, Maxima Enzyme Mix, with 
both reverse transcriptase (RT) and ribonuclease inhibitor, RiboLock, and finally, 1 μg of 
RNA, forming a total volume of 20 μL. The conditions for cDNA synthesis consisted in a first 
step at 25ºC for 10 minutes to allow primers to bind to the transcripts, followed by a second 
step at 50ºC for 15 minutes so that the RT can synthesize the cDNA strands, and a final step 
at 85ºC for 5 minutes to denature and degrade the remaining RNA. The total cDNA yield was 
quantified using NanoDrop ND-1000 spectrophotometer and stored at -20ºC until further use. 
PCR amplification was performed from SERCA2 cDNA previously synthesized, using six sets 
of primers, also specifically designed with Primer3 program, which span the whole sequence 
of SERCA2b that is transcribed (Table 3).  
For cDNA amplification, each PCR was performed according to PCR protocol for 
Phusion® High-Fidelity DNA Polymerase, as previously described, with annealing 
temperatures of 60 or 61ºC, a final magnesium chloride concentration of 1.5 mM or 3.0 mM, 
and a total volume of 25 μL.  
 
Table 3 | PCR primers and related parameters for amplification of SERCA2 from cDNA. 
a According to NCBI reference sequence NM_170665.4 
Exon Forward Primer Reverse Primer 
Coordinatesa 
(Forward; Reverse) 
Product size 
(bp) 
Annealing 
Temperature 
(ºC) 
1-6 aagaggaggaggggagac ttcacctgtgagaattgactgg 417-435; 1071-1092 676 61 
6-8 tggtgacaaagttcctgctg tgcagactgacatctggtttg 1008-1027; 1616-1636 629 
60 
  
  
  
  
8-13 gctcttggaactcgcagaat accccactctcgaatgacag 1501-1520; 2180-2199 699 
13-15 acccacattcgagttggaag gccacaatggtggagaagtt 2116-2135; 2755-2774 659 
15-18 gtgaacgatgctcctgctct aaagtccgggttgtcctctt 2653-2672; 3170-3189 537 
17-20 ctgctgcatggtggttcat ttcagcagaaatagacagttgctt 3092-3110; 3731-3754 663 
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3.5. Sequence analysis 
 
 PCR and RT-PCR products, generated from genomic and coding sequences of 
ATP2A2 respectively, were purified either from solution or TBE agarose gel slices, using 
Isolate II PCR and Gel Kit (Bioline). The clean-up protocol was based on a silica-membrane 
method which encompasses DNA-membrane fixation, membrane washing and DNA elution. 
PCR forward and/or reverse primers were added to the purified DNA fragments from each 
individual sample and submitted to GATC Biotech for bi-directional Sanger sequencing. This 
method uses terminator fluorescent dideoxynucleotides that allow the detection of each 
distinct nucleotide by laser and automatic storage of data in a computer. As a result, a series 
of fluorescence intensity peaks correspondent to each nucleotide can be observed in a 
chromatogram [56]. All chromatograms corresponding to PCR and RT-PCR fragments were 
carefully analyzed and the pathogenic mutation was found. 
 
 
3.6  Quantitative PCR 
 
 The expression of ATP2A2 gene was quantified by real-time PCR using the Maxima 
SYBR Green qPCR Master Mix (Thermo Fisher Scientific) and the CFX96 Touch™ Real-
Time System (Bio-Rad). Two sets of primers were designed to amplify both mutant and wild-
type transcripts (GGTGACAAGTTCCTGCTGA forward and AGTGTGCTTGATGAC 
AGAGACA reverse), or the wild-type transcripts only (TGTGCTCTTTGTAATGACTCTGC 
forward and AGAAAGACCCTTCAATTCGGTATCA reverse).  
 The set of primers designed strictly for wild-type transcripts allows the amplification 
of exon 10, which is missing in mutant mRNA while the set of primers for both wild-type and 
mutant anneals in the region of exons 6 and 7. The objective of this experiment was to assess 
relative levels of mutant and wild-type transcripts and look for a link between these 
expressions and the variable phenotype between the affected relatives. ATP2A2 mRNA 
expression was normalized by co-amplification of the housekeeping gene ACTB, coding for 
beta actin, which worked as an internal control. Primers used for evaluation of ACTB 
expression were a generous gift from Professor Graça Soveral 
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(CTGGGACGACATGGAGAAAATCTG forward and AGCCTGGATAGCAACGTACATG 
reverse). 
 
 
3.7  Western blotting 
 
 Lymphocytes isolated from 3 mL of whole blood were homogenized with RIPA lysis 
and extraction buffer (Pierce, Thermo Fisher Scientific) supplemented with HaltTM Protease 
and Phosphatase Inhibitor Cocktail (100x) (Thermo Fisher Scientific), followed by 
sonication. Lymphocyte homogenates were centrifuged for 10 minutes at 8000 rpm and the 
soluble fraction was collected for Western blot analysis to determine the expression level of 
the mutant protein in comparison with the wild-type SERCA2. Different procedures for 
protein extraction were performed in order to find the best strategy to assess SERCA2 
expression levels. 
 A quantity of 25 μg of total protein from each individual (evaluated by the 
Bicinchoninic Acid method) was mixed with Laemli loading buffer. Two sets of samples 
were studied as heated and unheated samples. The heated samples were denaturated at 95ºC 
for 5 minutes. All samples were briefly centrifuged and soluble fraction of cell lysates were 
resolved in 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred onto polyvinylidene difluoride membranes (GE Healthcare Life Sciences, 
Amersham Hybond) at 300 mA for 100 minutes at 4ºC. Blots were blocked with a solution 
containing 5% bovine serum albumin (BSA), TBS (1x), and 0.1% Tween® 20 for one hour at 
room temperature. Membranes were immediately incubated with rabbit polyclonal anti-
SERCA2 (dilution 1:10000; #4388 Cell Signaling) overnight at 4ºC, with gentle shaking. 
Membranes were probed with anti-rabbit IgG horseradish peroxidase-linked secondary 
antibody (dilution 1:2000; #7074, Cell Signaling Technologies, Inc.), followed by enhanced 
chemiluminescent blotting using SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific). Only after SERCA2 revelation the blots were incubated with 
primary antibody anti-β-actin (dilution 1:4000; Sigma-Aldrich), followed by secondary 
antibody incubation and revelation.  
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3.8  Genotype-Phenotype correlation 
 
 Since the family under study presents phenotypic variability among the affected 
individuals, it would be interesting to look for a genotype-phenotype correlation. 
Accordingly, all chromatograms from genomic DNA PCR products were analyzed closely in 
search for additional polymorphisms or insertions/deletions within exonic and intronic 
regions amplified by PCR, Additionally, ATP2A2 and SERCA2 expression levels would also 
be taken into account for the search of genotype-phenotype correlation. 
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4.  Results and Discussion 
 
 
4.1  Identification of the pathogenic mutation 
 
 Bi-directional sequence analysis of the genomic DNA revealed a transversion in the 
first nucleotide of intron 10 (c.1287+1G>T or IVS10+1G>T), which corresponds to the G of 
the wild-type splice donor site dinucleotide (Figure 8A1). Therefore, the pathogenic mutation 
is considered a splice-site mutation, as proven by 2% gel electrophoresis (Figure 8A2) and bi-
directional sequencing of RT-PCR products spanning exons 8 to 13, which confirmed that 
this variant affects the splicing process, leading to a shorter transcript where the skipping of 
full exon 10 is observed (Figure 8B). This mutant transcript contains a deletion of 103 base 
pairs (c.1185_1287del), originating a frameshift which putatively introduces a downstream 
premature stop codon (p.V395=fs*19). It was also observed that all four patients carry the 
same mutation in heterozigosity, whereas the unaffected individual carries the wild-type 
sequence in both alleles. For this reason, the unaffected individual was used as a negative 
control for the following experiments. 
 To understand what the splice site mutation does, it is important to know that splicing 
requires remarkable precision, which is granted by highly conserved intronic and exonic 
sequences and regulatory elements that are recognized by the spliceosome, a complex of 
small ribonucleoproteins (U1, U2, U5, U6/U4) and associated proteins [73]. Highly conserved 
intronic and/or exonic sequences include (1) the splice donor site GU and acceptor AG 
dinucleotides, recognized by the major spliceosome, at the 5’ and 3’ ends of the pre-mRNA, 
respectively; (2) the 5’ donor and 3’ acceptor splice site consensus sequences immediately 
upstream and downstream the GU and AG dinucleotides; and (3) the branch site, 
approximately 18 to 40 bp upstream the 3’ acceptor splice site [73].  Other relevant exonic 
and intronic sequences play a regulatory role either by promoting (splicing enhancer 
sequences) or inhibiting (splicing silencer sequences) the splicing process [73]. For instance, 
exon splicing enhancers are thought to compensate for the presence of splice sites with lower 
consensus values since it has been revealed that these sequences are in higher abundance in 
exons with “weak” splice acceptor sites [74]. 
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Mutant allele 
c.1287+1G>T in heterozygosity 
Wild-type allele 
 
1) Exon 10 + intronic boarders  
 
               
  
 
 
 
 
 
 
 
2) RT-PCR products (exon 8 – exon 13) 
 
   
 
 
 
 
 
 
 
 
 
                         M- Molecular marker (pBR322 x MspI, New England Biolabs) 
 
 
Figure 8A | Identification and expression of ATP2A2 pathogenic mutation. (1) Sequence analysis of the 
genomic sequence of ATP2A2 gene, corresponding to exon 10. The transversion IVS10+1G>T resulted in a 
splice-site mutation in intron 10. (2) RT-PCR products from every patient revealed that the splice site mutation 
yielded one wild-type allele transcript and a shorter transcript, while RT-PCR product from the unaffected 
member revealed two wild-type allele transcripts.  
 
699 bp 
596 bp 
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1) Fragment of cDNA sequence originating from the wild-type allele 
 
 
 
 
 
 
 
2) Fragment of cDNA sequence originating from the mutant allele 
 
 
 
 
 
Figure 8B | Sequence analysis of the coding sequence of ATP2A2 gene. Chromatograms correspondent to the 
wild-type sequence (1) and to the mutant sequence (2) which confirm the skipping of the entire region of exon 
10 from every smaller transcript. 
 
 
 Mutations in these highly conserved sequences can either result in two consequences: 
the most frequent one, exon skipping, when an exon is no longer recognized as such, or 
cryptic splice site use, when the resulting mature RNA lacks a portion of an exon or contains 
an additional sequence from an intron. In the reported case, the reason why c.1287+1G>T led 
to exon skipping rather than cryptic splice site may rely on potential spliceosome’s functional 
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response influencing factors, such as (1) local sequence context of the affected exon-intron 
junction and vicinities. For example, if the branch site of intron 10 exhibits a higher 
homology than the branch site sequence of intron 9; or if alternative splice sites with 
sufficient homology to the consensus sequence located in the vicinity are absent [73, 75]. (2) 
RNA secondary structure, since single stranded RNA might form base-pairing interactions 
and confer an unknown secondary structure to the mutant pre-transcript molecule in vivo, 
which might affect the access to the spliceosome [75]. And finally, (3) open reading frame 
(ORF) conservation since, in literature, it is postulated that exon skipping represents an 
evolutionary strategy towards better efficiency and stability as a spliceosome’s functional 
response to splice site mutations since it preserves the homology in the ORF of the mRNA 
molecule [75].  
 
 
4.2 ATP2A2 expression 
 
 Cells have evolved quality-control mechanisms to deal with their naturally limited 
precision of cellular and molecular processes. In eukaryotes, abnormal mRNA molecules with 
premature translation termination codons (PTCs) can sometimes be substrate to the 
surveillance pathway of Nonsense-Mediated Decay (NMD). According to the 50-55 bp rule, a 
PTC located less than 50-55 bp upstream the 3’-most exon-exon junction is not recognized by 
the NMD surveillance system and the respective mRNA is translated, generating a truncated 
protein [76, 77]. If the PTC is located upstream the 50-55 bp region, the abnormal mRNA can 
either be immediately degraded by NMD or have its translation repressed in case it escapes 
NMD [78]. Nevertheless, there have been reported exceptions to this rule [78, 79]. 
 In the studied case, the PTC derived from the skipping of exon 10 is located 74 bp 
upstream the 3’-most exon-exon junction (exon 11 – exon 12) (Figure 9). It is therefore 
expected that the abnormal transcript suffers nonsense codon recognition after splicing, which 
would lead to reduction of mRNA abundance by NMD. 
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Wild-type ATP2A2 mRNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Mutant ATP2A2 mRNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | Representation of fully spliced wild-type ATP2A2 product versus mutant ATP2A2 product. 
Exon-exon boundaries are indicated in green. The exon skipping-resulting frameshift starts in exon 11 (mutant 
ATP2A2 mRNA), which leads to a putative premature translation termination codon (PTC), identified in red, 
located upstream the 50-55 bp region, identified in blue.  
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The findings illustrated in figure 8A2 suggest that a small amount of the mutant 
transcript (596 bp fragment) escapes NMD. Additionally, the band corresponding to the wild-
type transcript (699 bp fragment) suggests an expression 50% inferior than that of the 
unaffected individual, who possesses an RT-PCR fragment equivalent to two copies of the 
wild-type ATP2A2 gene. In order to confirm this prediction, expression levels of both wild-
type- and mutant-allele-encoded transcripts were assessed by quantitative PCR. Results 
revealed a reduction of approximately 50-55% of wild-type plus mutant ATP2A2 expression 
when compared to the healthy subject, whose ATP2A2 gene expression was considered 100 % 
(Figure 10A). Next, the levels of wild-type gene expression alone were examined, allowing to 
conclude that the portion of wild-type mRNA from patients in figure 10A corresponds to 
approximately 36%, which leaves the mutant mRNA expression around residual levels of 
18% (Figure 10B). The levels of wild-type and mutant transcripts detected by qPCR are in 
agreement with figure 8A2, which suggests that out of all the mRNA molecules produced 
during transcription of mutant ATP2A2 gene, 18% fail to be recognized by NMD and could 
potentially lead to the generation of residual amounts of abnormal SERCA2. 
 
 
 A           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 | All patients showed ATP2A2 mRNA levels lower than 50% and residual levels of mutant 
mRNA. Quantitative PCR analysis was performed to quantify (A) expression levels of both wild-type and 
mutant transcripts and (B) wild-type transcripts alone. The data are presented as the mean ± SD of three 
independent experiments. 
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1    MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL  
51   ELVIEQFEDL LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA  
101  NAIVGVWQER NAENAIEALK EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI  
151  VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL TGESVSVIKH TDPVPDPRAV  
201  NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV ATEQERTPLQ  
251  QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV  
301  ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS  
351  DKTGTLTTNQ MSVCRMFILD RVEGDTCSLN EFTITGSTYA PIGEVHKDDK  
401  PVNCHQYDGL VELATICALC NDSALDYNEA KGVYEKVGEA TETALTCLVE  
451  KMNVFDTELK GLSKIERANA CNSVIKQLMK KEFTLEFSRD RKSMSVYCTP  
501  NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTSGV KQKIMSVIRE  
551  WGSGSDTLRC LALATHDNPL RREEMHLEDS ANFIKYETNL TFVGCVGMLD  
601  PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQDEDVTSK  
651  AFTGREFDEL NPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT  
701  GDGVNDAPAL KKAEIGIAMG SGTAVAKTAS EMVLADDNFS TIVAAVEEGR  
751  AIYNNMKQFI RYLISSNVGE VVCIFLTAAL GFPEALIPVQ LLWVNLVTDG  
801  LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG CYVGAATVGA  
851  AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFEGVDCAIF ESPYPMTMAL  
901  SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE  
951  PLPLIFQITP LNVTQWLMVL KISLPVILMD ETLKFVARNY LEPGKECVQP  
1001 ATKSCSFSAC TDGISWPFVL LIMPLVIWVY STDTNFSDMF WS 
 
4.3  SERCA2 expression 
 
 If 18% of the mutant mRNA ought to generate an abnormal protein, this would be 
truncated in the C-terminal end, containing 413 amino acids rather than the expected 1042 
(Figures 11A and 11B). The peptide chain would be normal until Val395, which is still 
preserved, but the remaining amino acids, from residues 396 to 413, would be different from 
the wild-type ones.  
 
Wild-type SERCA2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11A | Wild-type SERCA2b polypeptide sequence. Amino acids encoded by exon 10 is represented in 
violet. Wild-type SERCA2b parameters such as cDNA length, protein length, and protein weight are indicated 
below the polypeptide sequence. 
 
Exon 10 (Val395-Glu429) 
 
cDNA length (bp)  Protein length (aa)  Protein weight (kDa) 
3126    1042    114,62 
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1   MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL  
51  ELVIEQFEDL LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA  
101 NAIVGVWQER NAENAIEALK EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI  
151 VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL TGESVSVIKH TDPVPDPRAV  
201 NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV ATEQERTPLQ  
251 QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV  
301 ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS  
351 DKTGTLTTNQ MSVCRMFILD RVEGDTCSLN EFTITGSTYA PIGEVQRVCM                  
401 KKLEKLQRLL SLA 
 
Exon 9 (Met366-Val395)   Exon 11 (Gln396-Ala413) 
 
cDNA length (bp)  Protein length (aa)  Protein weight (kDa) 
1239    413    45,43 
 
 
 
Mutant SERCA2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11B | Putative C-terminus truncated mutant SERCA2 polypeptide sequence. Amino acids encoded 
by exon 9 and exon 11 are represented in green and blue colors, respectively. Mutant SERCA2b parameters such 
as cDNA length, protein length, and protein weight are indicated below the polypeptide sequence. 
 
 
 All mutant SERCA2 splicing variants would lose several highly conserved amino 
acids and motifs since it would no longer have most of P-domain, and completely lack the 
nucleotide-binding and hinge domains, the 5th stalk domain, the transmembrane domains 5 to 
10 or 11, where the calcium binding sites are located (TM5, 6, 8) and the 2b tail in case of the 
ubiquitous SERCA2b, which contributes to its high affinity for Ca2+ (Figure 12). 
Therefore, when assessing expression levels of SERCA2 protein, it might be expected 
to observe a band around 115 kDa corresponding to the wild-type pump, and another band of 
45 kDa corresponding to the mutant pump. When comparing heat-denaturated samples with 
unheated samples, it was found that heating prevented the detection of SERCA2 monomers in 
the blot, while enhancing the amount of oligomer (data not shown), as previously described 
[60]. Results show that wild-type SERCA2 proteins, when normalized to β-actin, present 
expression levels between 40 and 50% in DD patients when compared to the healthy 
individual (Figure 13), while no sign of mutant SERCA2 was detected (Figure 14).  
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There are three main explanations for the absence of mutant SERCA2 detection: (1) 
the amount of mutant SERCA2 derived from 18% of abnormal mRNA might be insufficient 
to generate detectable levels of protein; (2) the mutant protein is too immature to be stable and 
is immediately degraded by proteasomes; or (3) the remaining 18% PTC-containing mRNA 
molecules are not degraded by the NMD system but their translation is repressed by Nonsense 
Mediated Translational Repression (NMTR) mechanism, hence the synthesis of truncated 
protein is inhibited [78].  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 12 | Representation of SERCA2 domains and consequences of ATP2A2 mutation. Frameshift would 
start in exon 11 which encodes for P-domain and N-domain. However, since the frameshift leads to a premature 
STOP codon, the putative SERCA2 mutant would lack all the following domains (within red line).  
 
 
 A strategy to examine whether the mutant SERCA2 is synthesized and potentially 
interacts with wild-type SERCA2 to form dysfunctional dimers, as previously reported [61], 
would be to co-immunoprecipitate both proteins from cultured keratinocytes obtained from 
the patients. This method would require the use of two primary antibodies: one antibody 
specifically designed for mutant SERCA2, which could hybridize with an epitope within the 
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frameshift-encoded region of the polypeptide; and an antibody specific for wild-type 
SERCA2, that could hybridize with an epitope within the region encoded by exon 10, which 
is missing in the mutant protein. 
 
 
A 
 
             II.2                   I.2                    I.3 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 | Wild-type SERCA2 expression was severely reduced in patients when compared with the 
unaffected individual. (A) Naturally occurring SERCA2 proteins were severely reduced in affected individuals. 
Lymphocytes were lysed with 0.1% SDS and the resulting supernatants were resolved by 7.5% SDS-PAGE 
loaded with reduced, unheated samples. Anti-SERCA2 antibody was used for the western blots. After being 
washed, the same membrane was blotted with anti-beta-actin as the loading control. The marker used (left) was 
NZYColour Protein Marker II (Nzytech). (B) Percentage of wild-type SERCA2 Expression. Band intensity of 
SERCA2 was normalized with beta-actin. 
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Figure 14 | Absence of truncated protein in DD patients. Putative mutant SERCA2 (45 kDa) could not be 
detected by western blot. Lymphocytes were lysed with 0.1% SDS and the resulting supernatants were resolved 
by 7.5% SDS-PAGE loaded with reduced, unheated samples. Blots were incubated with anti-SERCA2 antibody 
only, without posterior anti-beta-actin incubation so that the band corresponding to beta-actin would not mask 
the presence of a band of 45 kDa, corresponding to the putative truncated SERCA2. The marker used (right) was 
NZYColour Protein Marker II (Nzytech). 
 
 
 To assess whether SERCA2 mutants are degraded by proteasomes, skin biopsies 
would be necessary so cells could be treated with a proteasome inhibitor such as MG132, 
followed by western blot analysis of SERCA2 [60]. In case the amount of mutant SERCA2 
fails to be detected when treated with the proteasome inhibitor, proteasome degradation 
hypothesis could be refuted.  
 On the other hand, a way to examine whether PTC-containing SERCA2 mRNA is not 
detected due to translational repression rather than instability of mRNA could be by polysome 
analysis, which would require the establishment of DD cell lines from the patients [80, 81]. 
This technique separates translated mRNAs on a sucrose gradient according to the number of 
bound ribosomes. Polysomal fractions can be analysed by RT-PCR and its relative levels in 
each fraction would reveal the translational status of the mutant SERCA2 mRNA [81]. Studies 
point that translational repression might depend on a putative cis-element residing in 3'-UTR, 
such as DNA transposons [80, 82]. Shen et al. revealed that miniature inverted-repeat 
transposable elements (MITEs) in the 3'-UTRs function as important regulators of translation, 
kDa   II.3          I.1            II.2     
SERCA2 
115 kDa 
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therefore these could be potential cis-element candidates [82]. Nonetheless, the role of 
retrotransposons in regulating the metabolism of mRNA should be further investigated in 
human cells. 
 In general, the results herein presented strongly suggest that haploinsufficiency is the 
mechanism underlying DD pathology in these patients, since a single normal copy of ATP2A2 
gene seems insufficient to maintain a normal phenotype. 
 
 
4.4  Genotype-phenotype correlations 
 
 4.4.1  Neuropsychiatric features 
 
 Calcium homeostasis depends on the rapid redistribution of Ca2+ ions into subcellular 
organelles, such as the ER, Golgi apparatus, and mitochondria, which serve as Ca2+ stores. 
The ER-Ca2+ stores rely on IP3Rs, RyRs and SERCA pumps. Despite the restricted tissue 
expression of SERCA2 isoforms a and c, SERCA2b is ubiquitously expressed in every cell, 
including neurons. A disruption of SERCA2-Ca2+ transport may consequently disrupt vital 
cellular/neuronal activities given calcium‘s role as second messenger in various intracellular 
cascades. Disruption of normal Ca2+ signaling has been associated with neuropsychiatric 
symptoms, such as depression and epilepsy, whose incidence is higher in DD population than 
that in general population [83].  
 In this case report, depressive moods and single suicide attempt have been reported in 
patient II.1 while patient II.3 has been diagnosed with epilepsy. The remaining patients do not 
show clinical history of neuropsychiatric symptoms. Moreover, additional nucleotide 
alterations were not detected within the amplified and sequenced PCR products spanning 
exons and exon-intron boundaries. This suggests that neuropsychiatric phenotypes are not a 
direct consequence of ATP2A2 mutations since the associated neuropsychiatric phenotypes in 
patients II.1 and II.3 are distinct and not segregated between the four relatives carrying the 
same ATP2A2 mutation. In agreement, Ruiz-Perez et al. support the absence of association 
between neuropsychiatric features and mutation class in DD patients [84]. According to these 
findings, the effects of ATP2A2 mutation in the brain may be a secondary consequence, 
however inconsistent. Nevertheless, ATP2A2 contains several introns with extensive size that 
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were not amplified; hence the absence/presence of nucleotide alterations or even large 
insertions or deletions in these regions were not examined. 
 According to previous studies, only lesional keratinocytes present cadherin disruption 
although ER Ca2+ levels are reduced in both lesional and non lesional keratinocytes. Besides 
their fundamental role in epitelial adhesion, cadherins are very important in neuronal 
functions too, such as synaptic specificity, synapse function, and plasticity [45, 83]. Literature 
points to the possibility that cadherins might be key regulators of neuron-neuron connectivity 
since it has been demonstrated their circuit specific expression throughout the brain [40]. 
However, the question “How?” remains to be answered.  
 Since every cell is depleted of Ca2+ in the ER, it is reasonable to suggest that ER Ca2+ 
depletion is not enough to cause mislocalization and altered trafficing of cadherins. Rather, 
altered Ca2+-induced cadherin expression, accumulation of somatic mutations in cadherin 
genes, and environmental factors might be underlying causes of this event. In fact, alterations 
in distinct cadherin genes have been associated with various neurological diseases [40].  
 
 
 4.4.2  Renal impairment 
 
 Besides neuropsychiatric disorders, previous reports have noted that DD patients may 
also present renal complications such as, polycystic kidney disease, renal agenesis, and 
horseshoe kidney [54, 55]. This is the first case reporting a patient (II.1) with DD in 
association with membranous nephropathy (MN), also known as membranous 
glomerulonephritis. Herein, it cannot be concluded whether this association with DD is by 
chance, therefore further studies on the incidence of renal impairment in DD population 
should be encouraged.  
 It is well established that ER stress is one of the major causes of kidney diseases [85]. 
As similarly reported in keratinocytes, ER stress-inducing agents, tunicamycin and 
thapsigargin, induce ER stress and autophagy in glomerular epithelial cells [60, 86]. In MN, 
immunoglobulin G and the complement form immune deposits in the 
subepithelial/intramembranous region of the glomeruli, which cause podocyte damage. 
Furthermore, as ATP2A2 mutations notably lead to desmosomal disruption in keratinocytes 
due to intracellular calcium imbalance, these could also contribute, in combination with 
environmental factors or medication, to the alteration of podocytes’ surface molecules by an 
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increase in ER stress, which may cause an immune response with antibody binding, 
complement activation, and cell damage [86, 87]. 
 Idiopathic MN is more common in adults of advancing age while secondary MN is 
caused by infections (hepatitis B and C, HIV, syphilis), tumors or medicines [88]. However, 
since patient II.1 is negative for the infections above-mentioned, it is important to record this 
case in order to alert physicians for a possible link between DD and renal impairment. 
 
 
 4.4.3  Corneal susceptibility to viral infection by Herpes Simplex  
  Virus (HSV)  
 
 Ocular involvement in DD remains relatively uncommon when compared with 
neuropsychiatric symptoms. Reported ocular features include dry eye syndrome with and 
without Sjögren’s syndrome, cystic lesions in the upper eyelid, recurrent herpes simplex 
keratitis, and corneal manifestations such as corneal ulceration, perforation, and peripheral 
epithelial nebular opacities, associated with irregular surface of central corneal epithelium 
[56, 57, 89, 90].  
 The keratotic debris of DD patients is vulnerable to localized or widespread recurrent 
colonization by bacteria, fungi, or virus. Impaired desmosomes of the corneal epithelium may 
reduce corneal protection and potentiate microbiological colonization of the skin and ocular 
surface [90]. Moreover, the impairment of adhesion molecules at the cell boarders, the loss of 
subsets of dendritic cells in the skin, and defect in local immune response might influence the 
susceptibility for viral and bacterial infections in DD patients, as could be the case of patient 
I.2 [91, 92]. 
 Adhesion molecules, such as e-cadherin, are known to facilitate lymphocyte homing, 
migration and distribution into epithelial tissue. Since lesional epidermis exhibits disrupted 
calcium signaling and altered e-cadherin traffic and localization, there is a huge chance that 
homotypic (e-cadherin-e-cadherin) and heterotypic (αEβ7 integrin-e-cadherin) adhesive 
interactions between intraepithelial lymphocytes and epithelial cells are impaired in DD 
pathology [93, 94]. With disrupted cadherins, leukocytes cannot be properly guided to the site 
of viral or bacterial infection. Therefore, it can be concluded that the increased risk of ocular 
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complications in DD may include herpes virus infection, as it occurs in patient I.2, who was 
already submitted to two cornea transplants. 
 
 
 4.4.4  Otological involvement 
 
 In these patients, hearing also seems to be affected by DD hallmarks, acantholysis and 
dyskeratosis, which lead to brownish-crusted papules in the outer ear, including the auditory 
canal, as previously described [95]. DD pathology in the ear has shown more severe 
consequences in patient II.1, whose hearing capacity from left ear is mostly loss and in need 
of surgical intervention.  
 
 Overall, no genotype-phenotype correlations have been found to support intrafamilial 
phenotypic variability. In conclusion, this phenomenon may rely on the influence of other 
nearby genes, pleiotropy of SERCA2, environmental factors, accumulation of somatic 
mutations, or pure chance. Moreover, since DD is a dominant condition, the phenotype of 
heterozygous individuals becomes more prone to external influences [96].  
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5.  Conclusion  
 
 Mutations responsible for DD are scattered over the entire ATP2A2 gene, hence it is 
not surprising that not every ATP2A2 mutation lead to DD through one single main 
mechanism: haploinsufficiency or dominant-negative effect. In this family, splice-site 
mutation c.1287+1G>T appears to cause DD phenotype through haploinsufficiency, i.e. in 
vivo, 40-50% of SERCA2 normal function is not enough to maintain a normal Ca2+ signaling 
in the skin, which is the organ that is mostly exposed to outside influence. The pathogenic 
variant detected in this family has been previously found in a Japanese female, but described 
at DNA level only [97]. In Portugal, the clinical aspect of DD has been described in a 28-
year-old male patient [98].  
 As the first molecular study of DD pathology in Portuguese patients, as well as the 
first molecular investigation of c.1287+1G>T at the transcriptional and translational levels, it 
adds knowledge to the worldwide mutational spectrum of the disease and, importantly, it 
contributes to genetic counseling since it allowed to discard a possible carrier status of the 
unaffected member of the family. This study also alerts physicians to the wide range of 
clinical manifestations in DD patients, including neuropsychiatric features, hearing loss, and 
corneal viral infections by HSV and glomerular nephritis which is, to our best knowledge, 
here firstly reported in association with DD.  
 Future perspectives would involve sequencing the promoter region of ATP2A2 gene in 
order to examine whether other variants could explain the wild-type SERCA2 mRNA 
expression levels below 50% that were observed in the patients. Furthermore, it would be 
relevant to sequence 3’UTR of SERCA2 mRNA given that this region is thought to hold 
additional cis-NMD regulatory elements. 
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